8 Einträge gefunden

1. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

   1. Reich, Kristian
   2. Papp, Kim A
   3. Blauvelt, Andrew
   4. Langley, Richard G
   5. Armstrong, April
   6. Warren, Richard B
   7. Gordon, Kenneth B

   2021 - Forschungsinformationssystem des UKE
2. Bimekizumab versus Adalimumab in Plaque Psoriasis

   1. Warren, Richard B
   2. Blauvelt, Andrew
   3. Bagel, Jerry
   4. Papp, Kim A
   5. Yamauchi, Paul
   6. Armstrong, April
   7. Langley, Richard G

   2021 - Forschungsinformationssystem des UKE
3. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study

   1. Papp, Kim A
   2. Weinberg, Mark A
   3. Morris, Alun
   4. Reich, Kristian

   2021 - Forschungsinformationssystem des UKE
4. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials

   1. Reich, Kristian
   2. Griffiths, Christopher E M
   3. Gordon, Kenneth B
   4. Papp, Kim A
   5. Song, Michael
   6. Randazzo, Bruce
   7. Li, Shu

   2020 - Forschungsinformationssystem des UKE
5. Upadacitinib in Adults With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Randomized, Placebo-Controlled Trial

   1. Guttman-Yassky, Emma
   2. Thaçi, Diamant
   3. Pangan, Aileen L
   4. Hong, H Chih-Ho
   5. Papp, Kim A
   6. Reich, Kristian
   7. Beck, Lisa A

   2020 - Forschungsinformationssystem des UKE
6. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

   1. Gordon, Kenneth B
   2. Strober, Bruce
   3. Lebwohl, Mark
   4. Augustin, Matthias
   5. Blauvelt, Andrew
   6. Poulin, Yves
   7. Papp, Kim A

   2018 - Forschungsinformationssystem des UKE
7. Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders. A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

   1. Blauvelt, Andrew
   2. Papp, Kim A
   3. Griffiths, Christopher E M
   4. Puig, Luis
   5. Weisman, Jamie
   6. Dutronc, Yves
   7. Kerr, Lisa Farmer

   2017 - Forschungsinformationssystem des UKE
8. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents.

   1. Papp, Kim A
   2. Strober, Bruce
   3. Augustin, Matthias
   4. Calabro, Steve
   5. Londhe, Anil
   6. Chevrier, Marc
   7. Investigators, PSOLAR

   2012 - Forschungsinformationssystem des UKE